Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Barboriak

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Neuro-Oncology|February 4, 2015
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialKathleen M Schmainda, Zheng Zhang, Melissa Prah, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2011
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parametersOana I Craciunescu, David S Yoo, Esi Cleland, et al.
Radiology|November 28, 2018
Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 StudyDaniel P Barboriak, Zheng Zhang, Pratikkumar Desai, et al.
Neuro-Oncology|March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology|June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyJerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology|May 7, 2013
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677Eva-Maria Ratai, Zheng Zhang, Bradley S Snyder, et al.
AJNR. American Journal of Neuroradiology|October 17, 2003
Correlation of early dynamic CT perfusion imaging with whole-brain MR diffusion and perfusion imaging in acute hemispheric strokeJames D Eastwood, Michael H Lev, Max Wintermark, et al.
Radiology|January 5, 2002
CT perfusion scanning with deconvolution analysis: pilot study in patients with acute middle cerebral artery strokeJames D Eastwood, Michael H Lev, Tarek Azhari, et al.
Translational Oncology|December 4, 2009
Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sourcesCharles R Meyer, Samuel G Armato, Charles P Fenimore, et al.
International Journal of Oncology|February 13, 2015
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastomaBenjamin M Ellingson, Eunhee Kim, Davis C Woodworth, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Neuro-Oncology|February 4, 2015
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialKathleen M Schmainda, Zheng Zhang, Melissa Prah, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2011
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parametersOana I Craciunescu, David S Yoo, Esi Cleland, et al.
Radiology|November 28, 2018
Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 StudyDaniel P Barboriak, Zheng Zhang, Pratikkumar Desai, et al.
Neuro-Oncology|March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology|June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyJerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.
Neuro-Oncology|May 7, 2013
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677Eva-Maria Ratai, Zheng Zhang, Bradley S Snyder, et al.
AJNR. American Journal of Neuroradiology|October 17, 2003
Correlation of early dynamic CT perfusion imaging with whole-brain MR diffusion and perfusion imaging in acute hemispheric strokeJames D Eastwood, Michael H Lev, Max Wintermark, et al.
Radiology|January 5, 2002
CT perfusion scanning with deconvolution analysis: pilot study in patients with acute middle cerebral artery strokeJames D Eastwood, Michael H Lev, Tarek Azhari, et al.
Translational Oncology|December 4, 2009
Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sourcesCharles R Meyer, Samuel G Armato, Charles P Fenimore, et al.
International Journal of Oncology|February 13, 2015
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastomaBenjamin M Ellingson, Eunhee Kim, Davis C Woodworth, et al.
Pageof 5